Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure

Pooled data from trials comparing nesiritide with dobutamine for treatment of acute decompensated congestive heart failure were combined with national hospital cost data in an economic model. Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs.

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2003-09, Vol.92 (5), p.631-633
Main Authors: de Lissovoy, Gregory, Stier, David M., Ciesla, Gabrielle, Munger, Mark, Burger, Andrew J.
Format: Article
Language:English
Subjects:
Acute Disease
Age Distribution
Aged
Biological and medical sciences
Cardiotonic agents
Cardiotonic Agents - economics
Cardiotonic Agents - therapeutic use
Cardiovascular system
Dobutamine - economics
Dobutamine - therapeutic use
Drug Costs - statistics & numerical data
Drug therapy
Economics
Female
Heart failure
Heart Failure - drug therapy
Heart Failure - economics
Heart Failure - mortality
Hospital Costs - statistics & numerical data
Humans
Life Expectancy
Male
Medical sciences
Middle Aged
Models, Econometric
Monte Carlo Method
Natriuretic Agents - economics
Natriuretic Agents - therapeutic use
Natriuretic Peptide, Brain
Patient Admission - economics
Patients
Pharmacology. Drug treatments
Predictive Value of Tests
Sex Distribution
Survival Analysis
Treatment Outcome
United States - epidemiology
Value of Life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pooled data from trials comparing nesiritide with dobutamine for treatment of acute decompensated congestive heart failure were combined with national hospital cost data in an economic model. Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs.
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(03)00742-2